Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on November 9, 2015. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2015. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, CA.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus prior periods. It solely references the issuance of a press release containing the comparative financial results for the periods ended September 30, 2015.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other documents except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 9, 2015) for actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones or clinical trial updates mentioned in the referenced press release.
- Confirm the company's cash runway and burn rate as detailed in the full financial statements.
- Note that the registrant name in the filing header is Trovagene, Inc., despite the request metadata referencing "Cardiff Oncology, Inc."